X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2318) 2318
Publication (170) 170
Book Review (19) 19
Book Chapter (11) 11
Conference Proceeding (3) 3
Book / eBook (2) 2
Dissertation (2) 2
Government Document (2) 2
Magazine Article (2) 2
Newspaper Article (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (1166) 1166
humans (1145) 1145
male (1066) 1066
index medicus (952) 952
oximes (753) 753
female (679) 679
rats (539) 539
oximes - pharmacology (535) 535
pharmacology & pharmacy (489) 489
toxicology (423) 423
oximes - administration & dosage (410) 410
mice (350) 350
adult (343) 343
oximes - therapeutic use (336) 336
middle aged (326) 326
acetylcholinesterase (307) 307
aged (219) 219
acetylcholinesterase - metabolism (213) 213
soman (213) 213
oxime (211) 211
oximes - chemistry (207) 207
dose-response relationship, drug (200) 200
technetium tc 99m exametazime (199) 199
analysis (185) 185
efficacy (182) 182
biochemistry & molecular biology (180) 180
cholinesterase reactivators - pharmacology (180) 180
rats, wistar (179) 179
melanoma - drug therapy (170) 170
poisoning (168) 168
organophosphorus compounds (167) 167
oximes - pharmacokinetics (163) 163
nerve agents (161) 161
atropine (160) 160
neurosciences (157) 157
pyridinium compounds - pharmacology (157) 157
imidazoles - administration & dosage (156) 156
organotechnetium compounds (156) 156
brain (155) 155
time factors (155) 155
dogs (151) 151
hi-6 (150) 150
tomography, emission-computed, single-photon (145) 145
reactivation (143) 143
organophosphate poisoning (140) 140
oximes - adverse effects (140) 140
melanoma (139) 139
treatment outcome (135) 135
tabun (132) 132
chemistry, medicinal (131) 131
oncology (129) 129
inhibition (124) 124
obidoxime (124) 124
proto-oncogene proteins b-raf - genetics (124) 124
toxicity (122) 122
antidotes - therapeutic use (118) 118
kinetics (116) 116
proto-oncogene proteins b-raf - antagonists & inhibitors (116) 116
structure-activity relationship (115) 115
cholinesterase inhibitors - toxicity (114) 114
mutation (113) 113
in-vitro (112) 112
administration, oral (110) 110
research (109) 109
sarin (109) 109
brain - diagnostic imaging (107) 107
pharmacokinetics (107) 107
brain - drug effects (105) 105
nerve gas (105) 105
rats, sprague-dawley (104) 104
pralidoxime (103) 103
cholinesterase reactivators - therapeutic use (102) 102
pyrimidinones - administration & dosage (101) 101
pyridones - administration & dosage (100) 100
lethal dose 50 (99) 99
organophosphate (99) 99
radiology, nuclear medicine & medical imaging (99) 99
brain - metabolism (97) 97
milbemycin oxime (97) 97
molecular structure (97) 97
organophosphates (97) 97
antidotes - pharmacology (96) 96
therapy (95) 95
vemurafenib (95) 95
atropine - pharmacology (93) 93
drug therapy, combination (93) 93
rat (93) 93
adolescent (91) 91
in vitro techniques (91) 91
atropine - therapeutic use (90) 90
pyridinium compounds - therapeutic use (90) 90
cancer (89) 89
oximes - metabolism (89) 89
cholinesterase inhibitors - poisoning (88) 88
enzymes (88) 88
skin neoplasms - drug therapy (88) 88
dabrafenib (87) 87
antineoplastic combined chemotherapy protocols - therapeutic use (83) 83
care and treatment (82) 82
cholinesterase inhibitors - pharmacology (81) 81
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2254) 2254
Japanese (17) 17
French (13) 13
Czech (10) 10
Russian (10) 10
German (9) 9
Polish (6) 6
Serbian (4) 4
Croatian (3) 3
Italian (3) 3
Spanish (3) 3
Hebrew (2) 2
Bulgarian (1) 1
Chinese (1) 1
Danish (1) 1
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 6, pp. 1102 - 1109.e1
Background BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events. Objective We sought to investigate the cutaneous safety... 
Dermatology | cutaneous adverse event | rash | histology | inflammation | therapy | squamous cell carcinoma | squamous cell carcinoma therapy | ACTIVATION | IMPROVED SURVIVAL | OPEN-LABEL | DERMATOLOGY | METASTATIC MELANOMA | MEK INHIBITION | PATHWAY | RESISTANCE | RAF INHIBITORS | MUTATIONS | VEMURAFENIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Young Adult | Pyridones - administration & dosage | Carcinoma, Squamous Cell - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Azetidines - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Indoles - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma - mortality | Complications and side effects | Medical colleges | Melanoma
Journal Article
PLOS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, p. e0125021
The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance.... 
COLON-CANCER | MELANOMA | MEK INHIBITION | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | SYNTHETIC LETHAL INTERACTION | RESISTANCE | BRAF | KINASE INHIBITOR | BETA-CATENIN | EGFR | Triazoles - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Aza Compounds - pharmacology | Cell Line, Tumor - drug effects | Indazoles - administration & dosage | Quinolines - administration & dosage | Indoles - administration & dosage | Quinolines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Melanoma - genetics | Indoles - pharmacology | Pyrimidinones - pharmacology | Molecular Targeted Therapy - methods | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins p21(ras) - metabolism | Aza Compounds - administration & dosage | Imidazoles - pharmacology | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins c-myc - metabolism | beta Catenin - metabolism | beta Catenin - genetics | Indazoles - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Triazoles - pharmacology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Oxazoles - administration & dosage | Oximes - pharmacology | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Oxazoles - pharmacology | Proto-Oncogene Proteins c-myc - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - pharmacology | Sulfonamides - administration & dosage | Drug therapy, Combination | Drug resistance | Drug therapy | Health aspects | Analysis | Melanoma
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination... 
trametinib | melanoma | durable outcomes | BRAF | metastatic | dabrafenib | MULTICENTER | OPEN-LABEL | COMBINATION | TRIAL | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | POOLED ANALYSIS | NIVOLUMAB | IPILIMUMAB | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Original
Journal Article
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 12/2014, Volume 281, Issue 3, pp. 254 - 265
The currently fielded pre-hospital therapeutic regimen for the treatment of organophosphorus (OP) poisoning in the United States (U.S.) is the administration... 
Oxime | Efficacy | Guinea pig | Intramuscular | Toxicity | HYDROXAMIC ACIDS | PYRIDINIUM OXIMES | SOMAN | HUMAN ACETYLCHOLINESTERASE | NERVE AGENTS | TABUN | IN-VIVO REACTIVATION | CYCLOSARIN | SARIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | BRAIN | Atropine - therapeutic use | Cholinesterase Reactivators - administration & dosage | Cholinesterase Inhibitors - toxicity | Atropine - adverse effects | Oximes - adverse effects | Muscarinic Antagonists - adverse effects | Cholinesterase Inhibitors - chemistry | Oximes - administration & dosage | Pyridinium Compounds - administration & dosage | Pyridinium Compounds - therapeutic use | Oximes - therapeutic use | Male | Organophosphate Poisoning - drug therapy | Pyridinium Compounds - adverse effects | Antidotes - administration & dosage | Muscarinic Antagonists - therapeutic use | Chemical Warfare Agents - chemistry | Cholinesterases - blood | Organophosphate Poisoning - physiopathology | Drug Therapy, Combination - adverse effects | Injections, Subcutaneous | Cholinesterase Reactivators - adverse effects | Guinea Pigs | Drug Administration Schedule | Cholinesterase Reactivators - therapeutic use | Injections, Intramuscular | Pesticides - antagonists & inhibitors | Random Allocation | Muscarinic Antagonists - administration & dosage | Animals | Cholinesterase Inhibitors - administration & dosage | Pesticides - toxicity | Organophosphate Poisoning - blood | Antidotes - adverse effects | Atropine - administration & dosage | Chemical Warfare Agents - toxicity | Drug Monitoring | Antidotes - therapeutic use | Analysis | Enzyme inhibitors | Pesticides | Index Medicus | CHOLINESTERASE | ATROPINE | GUINEA PIGS | CHLORINE | BLOOD-BRAIN BARRIER | CENTRAL NERVOUS SYSTEM | SYMPTOMS | TOXICITY | STANDARD OF LIVING | US FDA | 60 APPLIED LIFE SCIENCES | MOLECULAR WEIGHT | PESTICIDES | LETHAL DOSES | OXIMES | THERAPY | CHEMICAL WARFARE AGENTS | POISONING | BLOOD | toxicity | intramuscular | guinea pig | oxime | efficacy
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The Oncologist, ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
Toxicology, ISSN 0300-483X, 2007, Volume 243, Issue 3, pp. 311 - 316
Abstract The potency of newly developed monoxime bispyridinium compounds (K156, K203) in reactivating tabun-inhibited acetylcholinesterase and reducing... 
Emergency | Obidoxime | Tabun | K156 | K203 | Rats | Trimedoxime | Mice | HI-6 | Acetylcholinesterase | trimedoxime | ACETYLCHOLINESTERASE REACTIVATORS | EFFICACY | IN-VIVO METHODS | ANTIDOTAL TREATMENT | acetylcholinesterase | INHIBITED ACETYLCHOLINESTERASE | obidoxime | mice | NERVE AGENTS | H OXIMES | PHARMACOLOGY & PHARMACY | PRALIDOXIME | TOXICOLOGY | rats | ORGANOPHOSPHORUS COMPOUNDS | tabun | CURRENTLY AVAILABLE OXIMES | Atropine - therapeutic use | Cholinesterase Reactivators - administration & dosage | Atropine - chemistry | Seizures - prevention & control | Rats, Wistar | Species Specificity | Cholinesterase Inhibitors - chemistry | Oximes - administration & dosage | Pyridinium Compounds - administration & dosage | Pyridinium Compounds - therapeutic use | Oximes - therapeutic use | Male | Antidotes - administration & dosage | Chromatography, High Pressure Liquid | Toxicity Tests, Acute - methods | Seizures - chemically induced | Cholinesterase Inhibitors - poisoning | Molecular Structure | Obidoxime Chloride - therapeutic use | Drug Therapy, Combination | Pyridinium Compounds - chemistry | Organophosphates - administration & dosage | Antidotes - chemistry | Seizures - enzymology | Acetylcholinesterase - blood | Trimedoxime - chemistry | Cholinesterase Reactivators - therapeutic use | Obidoxime Chloride - chemistry | Injections, Intramuscular | Lethal Dose 50 | Trimedoxime - administration & dosage | Cholinesterase Reactivators - chemistry | Oximes - chemistry | Animals | Trimedoxime - therapeutic use | Cholinesterase Inhibitors - administration & dosage | Obidoxime Chloride - administration & dosage | Organophosphates - chemistry | Atropine - administration & dosage | Organophosphate Poisoning | Acetylcholinesterase - metabolism | Antidotes - therapeutic use
Journal Article